New hope for rare bleeding disorder: VONVENDI trial launches in china

NCT ID NCT07129343

Recruiting now Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called VONVENDI (recombinant von Willebrand factor) in 20 Chinese adults with von Willebrand disease, a bleeding disorder. The goal is to see if it is safe and helps control bleeding during surgery or dental procedures, sometimes combined with another drug (ADVATE). Participants receive the drug by IV and are followed for about 14 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

von Willebrand disease (hereditary or acquired)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VON WILLEBRAND DISEASE (VWD)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
RECRUITING

Tianjin, 300052, China
Jinan Central Hospital
RECRUITING

Jihan, 250013, China
Nanfang Hospital Southern Medical University
RECRUITING

Guangzhou, 510515, China
Peking Union Medical College Hospital
RECRUITING

Beijing, 100006, China
Ruijin Hospital Shanghai Jiaotong University School of Medicine
RECRUITING

Shanghai, 201801, China
The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, 215005, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITING

Wuhan, 430032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.